source
- Boehringer Ingelheim boosts Variant Bio partnership with $250 million for cardiovascular researchBoehringer Ingelheim announced an expansion of its collaboration with Variant Bio. The partnership will now include cardiovascular disease research, broadening its original scope. The deal value…
- FDA shift sparks renewed pharma and VC focus on osteoporosis drug developmentThe FDA recently altered its regulatory framework for osteoporosis medicines, prompting a wave of renewed interest across the pharmaceutical sector. Earlier, drugs from Eli Lilly, Merck, Novartis…